摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-环己基-1-(2-甲氧基苯基)甲亚胺 | 123334-93-0

中文名称
N-环己基-1-(2-甲氧基苯基)甲亚胺
中文别名
——
英文名称
Cyclohexyl-[1-(2-methoxy-phenyl)-meth-(E)-ylidene]-amine
英文别名
Cyclohexanamine, N-[(2-methoxyphenyl)methylene]-;N-cyclohexyl-1-(2-methoxyphenyl)methanimine
N-环己基-1-(2-甲氧基苯基)甲亚胺化学式
CAS
123334-93-0
化学式
C14H19NO
mdl
——
分子量
217.311
InChiKey
BWRTYSRMCAZULB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    21.6
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    N-环己基-1-(2-甲氧基苯基)甲亚胺 在 sodium tetrahydroborate 、 potassium carbonate 作用下, 以 乙醇丙酮 为溶剂, 反应 20.0h, 生成 C17H27NO2
    参考文献:
    名称:
    N-手性氧化胺的催化不对称合成
    摘要:
    N-手性氧化胺的直接不对称合成是通过双金属钛催化剂完成的(高达91:9 er)。位于N立体中心的γ位置的羟基可通过三价胺底物的动态动力学拆分实现所需的N氧化。该方法进一步扩展到具有预先存在的立体中心的外消旋γ-氨基醇的动力学拆分,提供了一类重要的对映体富集的(高达99.9:0.1 er)构建基块,否则这些合成基团很难合成。
    DOI:
    10.1002/anie.201606354
  • 作为产物:
    描述:
    2-甲氧基苯甲醇环己胺 在 calcium nitride 、 N,N'-bis(salicylidene)-1,2-cyclohexanediaminomanganese(III) chloride 作用下, 以 甲苯 为溶剂, 反应 48.0h, 以90%的产率得到N-环己基-1-(2-甲氧基苯基)甲亚胺
    参考文献:
    名称:
    锰(iii)salen催化的醇脱氢的开发和机理研究†
    摘要:
    介绍了用于醇的无受体脱氢的锰 ( III ) 催化剂的第一个例子。N , N' -双(水杨基)-1,2-环己烷二氨基锰 ( III ) 氯化物 ( 2 ) 已被证明可催化从各种醇和胺直接合成亚胺,并释放氢气。该机制已经用标记的底物进行了实验研究,并在理论上用 DFT 计算进行了研究。结果表明金属-配体双功能途径,其中salen配体中的两个亚胺基团首先被还原形成锰(III) 酰胺络合物作为催化活性物质。然后通过逐步的外球氢转移发生醇的脱氢,产生氢化锰( III ),从中释放氢气。
    DOI:
    10.1039/c8sc03969k
点击查看最新优质反应信息

文献信息

  • In Situ Generated Cobalt Catalyst for the Dehydrogenative Coupling of Alcohols and Amines into Imines
    作者:Fabrizio Bottaro、Robert Madsen
    DOI:10.1002/cctc.201900392
    日期:2019.6.6
    An in situ formed cobalt catalyst is developed from cobalt(II)bromide, bis[2‐(diisopropylphosphino)‐4‐methylphenyl]amine and zinc metal. The catalyst mediates the acceptorless dehydrogenative coupling of alcohols and amines into imines with the release of hydrogen gas and the transformation is applied to the synthesis of a variety of imines from different alcohols and amines. The mechanism is investigated
    用溴化钴(II),双[2-(二异丙基膦基)-4-甲基苯基]胺和金属锌开发了原位形成的钴催化剂。该催化剂介导醇和胺的无受体脱氢偶联成亚胺,并释放出氢气,该转化被用于由不同的醇和胺合成各种亚胺。用标记的底物研究了该机理,并且基于结果,钴(I)PNP配合物被认为是催化活性物质,其通过金属配体双功能途径从醇中提取氢气。
  • Benzimidazole derivatives, their production and use
    申请人:——
    公开号:US20010047020A1
    公开(公告)日:2001-11-29
    Benzimidazole derivatives of the formula (I): 1 wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R 1 is hydrogen or an optionally substituted hydrocarbon residue; R 2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O) m — or —N(R 4 )— wherein m is an integer of 0, 1 or 2 and R 4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
    式(I)中的苯并咪唑衍生物:其中环A是苯环,除了R'基外还可选含取代基;R1是氢或可选取代的碳氢基团;R2是能够形成负离子或可转化为负离子的基团;X是直接键或具有原子长度不超过二的间隔物,位于苯基团和苯基团之间;R'是羧基、其酯、酰胺或能够形成负离子或可转化为负离子的基团;Y是-O-、-S(O)m-或-N(R4)-,其中m为0、1或2的整数,R4为氢或可选取代的烷基团;n为1或2的整数;以及其药学上可接受的盐,具有强效的血管紧张素II拮抗活性和降压活性,因此可用作治疗循环系统疾病如高血压病、心脏病(如心动过速、心力衰竭、心肌梗塞等)、中风、脑出血、肾炎等的治疗剂。
  • Benzimidazole derivatives and use thereof
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US05705517A1
    公开(公告)日:1998-01-06
    Benzimidazole derivatives of the formula (I): ##STR1## wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R' group; R' is hydrogen or an optionally substituted hydrocarbon residue; R.sup.2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R' is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is --O--, --S(O).sub.m -- or --N(R.sup.4)-- wherein m is an integer of 0, 1 or 2 and R.sup.4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin II antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
    公式(I)的苯并咪唑衍生物:##STR1## 其中环A是苯环,除了R'基外还可以包含取代基;R'是氢或可选的取代的碳氢残基;R.sup.2是能够形成负离子或可转化为负离子的基团;X是直接键或具有原子长度为2或更少的间隔物,位于苯基团和苯基团之间;R'是羧基,其酯,其酰胺或能够形成负离子或可转化为负离子的基团;Y是--O--,--S(O).sub.m--或--N(R.sup.4)--,其中m是0、1或2的整数,R.sup.4是氢或可选的取代的烷基;n是1或2的整数;以及其药物可接受的盐具有强大的血管紧张素II拮抗活性和降压活性,因此可用作治疗循环系统疾病,如高血压病,心脏病(例如高心率,心力衰竭,心肌梗死等),中风,脑中风,肾炎等的治疗剂。
  • Benzimidazole compounds, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US06355808B2
    公开(公告)日:2002-03-12
    Benzimidazole derivatives of the formula (I): wherein the ring A is a benzene ring which may optionally contain substitution in addition to the R′ group; R1 is hydrogen or an optionally substituted hydrocarbon residue; R2 is a group capable of forming an anion or a group convertible thereinto; X is a direct bond or a spacer having an atomic length of two or less between the phenylene group and the phenyl group; R′ is carboxyl, an ester thereof, an amide thereof or a group capable of forming an anion or convertible to an anion; Y is —O—, —S(O)m— or —N(R4)— wherein m is an integer of 0, 1 or 2 and R4 is hydrogen or an optionally substituted alkyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof, have potent angiotensin Π antagonistic activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases (e.g. hypercardia, heart failure, cardiac infarction, etc.), strokes, cerebral apoplexy, nephritis, etc.
    公式(I)的苯并咪唑衍生物:其中环A是苯环,除R′基外还可以含有取代基;R1是氢或可选的取代的碳氢残基;R2是能够形成负离子或可转化为负离子的基团;X是直接键或具有原子长度为2或更少的间隔物,在苯基团和苯基团之间;R′是羧基,其酯,其酰胺或能够形成负离子或可转化为负离子的基团;Y是-O-,-S(O)m-或-N(R4)-,其中m是0、1或2的整数,R4是氢或可选的取代的烷基;n是1或2的整数;以及其药学上可接受的盐,具有强大的血管紧张素Π拮抗活性和降压活性,因此可用作治疗循环系统疾病(如高血压病,心脏病(如心肌肥厚,心力衰竭,心肌梗塞等),中风,脑卒中,肾炎等)的治疗剂。
  • Benzaldimines as ligands for palladium in Suzuki–Miyaura reactions
    作者:Dipankar Srimani、Amitabha Sarkar
    DOI:10.1016/j.tetlet.2008.08.056
    日期:2008.10
    Schiff bases derived from substituted benzaldehydes are effective ligands for palladium(0) in the Suzuki-Miyaura coupling of phenylboronic acid with aryl, benzyl and allyl bromides under mild conditions. (c) 2008 Elsevier Ltd. All rights reserved.
查看更多